Stay updated with breaking news from Viveve Systems. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Topline results of the 12-month primary efficacy endpoint anticipated in January 2023Positive results may support a de novo marketing application for a new U.S. indication for treatment of stress urinary
Patent further strengthens Viveve's novel dual-energy technology intellectual property portfolio as company plans for completion of pivotal PURSUIT clinical trialENGLEWOOD, CO / ACCESSWIRE / December 1
Patent issuance further strengthens Viveve's intellectual property portfolio for the treatment of female stress urinary incontinenceENGLEWOOD, CO / ACCESSWIRE / October 4, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE)
New branding reflects Company's vision to be the leader in the treatment of Stress Urinary Incontinence in WomenCompletion of PURSUIT follow-up visits anticipated by the end of 2022 with topline results
ENGLEWOOD, CO / ACCESSWIRE / September 1, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today